A New Path for Bio, Anti-Aging

Editor's NoteAnti-aging is no longer a peripheral topic within the wellness industry. Global big pharma companies are now directly targeting aging itself as the focus of new drug development, pouring billions of dollars into the sector and fundamentally rewriting the rules of the game. Korea, which once took the earliest steps forward, now finds itself trailing far behind—held back by a lack of initial investment, the absence of a control tower, and fragmented government policies. However, opportunities remain for Korea in the areas of data, regenerative medicine, and precision diagnostics infrastructure. The Asia Business Daily examines the current state and future of the global anti-aging industry, exploring the path Korea must take going forward. ① "The Fight Against Aging" Becomes a Global New Industry② Big Pharma Has Yet to Solve Anti-Aging Drugs—A Window Opens for Korea③ Samsung Was Ahead of Google in Anti-Aging Research: Why Is It Now 13 Years Behind?④ K-BIGHART Dreams of a Kore

Editor's NoteAnti-aging is no longer just a peripheral topic within the wellness industry. Global big pharma companies are now directly targeting aging itself with new drugs, boldly investing billions of dollars and rewriting the "rules of the game." Although Korea took its first step faster than anyone else, the country has since fallen far behind due to a lack of early-stage investment, the absence of a control tower, and fragmented policies. However, there are still opportunities for Korea in the areas of data, regenerative medicine, and precision diagnostics infrastructure. The Asia Business Daily examines the current state and future of the global anti-aging industry and seeks a path forward for Korea. ① "The Fight Against Aging": Establishing a Global New Industry ② Untapped Opportunities in Korea: Anti-Aging Drugs Even Big Pharma Hasn't Solved ③ Why Did Samsung's Anti-Aging Research, Once Ahead of Google, Fall 13 Years Behind? ④ K-BigHeart's Dream of a Korean Version of IMEC The

Editor's NoteAnti-aging is no longer confined to the margins of the wellness industry. Global pharmaceutical giants are now directly targeting aging itself as a new drug indication, pouring billions of dollars into the field and fundamentally rewriting the rules of the game. Although Korea was once among the earliest to take the first step, it has since fallen far behind due to a lack of early investment, an absence of a control tower, and fragmented policies. However, in areas such as data, regenerative medicine, and precision diagnostics infrastructure, opportunities remain open to us. The Asia Business Daily examines the current state and future of the global anti-aging industry and explores the road ahead for Korea. ① 'The Battle Against Aging' Becomes a New Global Industry② Even Big Pharma Has Not Cracked Anti-Aging Drugs, but There Are 'Opportunities' for Korea③ Why Did Samsung, Once Ahead of Google, Fall 13 Years Behind in Anti-Aging Research?④ K-BigHeart Dreams of Becoming the

Editor's NoteAnti-aging is no longer a peripheral discourse in the wellness industry. Global big pharma companies are now directly targeting aging itself as a subject for new drug development, pouring billions of dollars into the field and fundamentally rewriting the rules of the game. Although Korea was among the first to take initial steps, it has since fallen behind due to a lack of early investment, the absence of a central control tower, and fragmented policies. However, there are still opportunities for Korea in terms of data, regenerative medicine, and precision diagnostics infrastructure. The Asia Business Daily examines the current state and future of the global anti-aging industry and explores the path forward for Korea. ① "The Fight Against Aging" Establishes Itself as a Global New Industry② Anti-Aging Drugs Even Big Pharma Couldn't Solve—A 'Niche' Opens for Korea③ Samsung's Anti-Aging Research Was Faster Than Google's—Why Is It Now 13 Years Behind?④ K-BigHeart Aims to Becom